Benjamin Challis

List of Publications by Year
in descending order

34 papers	999 citations	567281 15 h-index	454955 30 g-index
37 all docs	37 docs citations	37 times ranked	1773 citing authors

#	Article	IF	Citations
1	A missense mutation disrupting a dibasic prohormone processing site in pro-opiomelanocortin (POMC) increases susceptibility to early-onset obesity through a novel molecular mechanism. Human Molecular Genetics, 2002, 11, 1997-2004.	2.9	249
2	Rare variant contribution to human disease in 281,104 UK Biobank exomes. Nature, 2021, 597, 527-532.	27.8	224
3	CT Characteristics of Pheochromocytoma: Relevance for the Evaluation of Adrenal Incidentaloma. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 312-318.	3.6	96
4	A review of the tumour spectrum of germline succinate dehydrogenase gene mutations: Beyond phaeochromocytoma and paraganglioma. Clinical Endocrinology, 2020, 93, 528-538.	2.4	36
5	Clinical and Molecular Features of Renal and Pheochromocytoma/Paraganglioma Tumor Association Syndrome (RAPTAS): Case Series and Literature Review. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4013-4022.	3.6	35
6	Peptidomic analysis of endogenous plasma peptides from patients with pancreatic neuroendocrine tumours. Rapid Communications in Mass Spectrometry, 2018, 32, 1414-1424.	1.5	32
7	Familial Adrenocortical Carcinoma in Association With Lynch Syndrome. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2269-2272.	3.6	27
8	Genetic testing for hereditary hyperparathyroidism and familial hypocalciuric hypercalcaemia in a large UK cohort. Clinical Endocrinology, 2020, 93, 409-418.	2.4	27
9	Clinical Practice Guidance: Surveillance for phaeochromocytoma and paraganglioma in paediatric succinate dehydrogenase gene mutation carriers. Clinical Endocrinology, 2019, 90, 499-505.	2.4	25
10	Translating In Vivo Metabolomic Analysis of Succinate Dehydrogenaseâ€“Deficient Tumors Into Clinical Utility. JCO Precision Oncology, 2018, 2, 1-12.	3.0	22
11	Familial adult onset hyperinsulinism due to an activating glucokinase mutation: implications for pharmacological glucokinase activation. Clinical Endocrinology, 2014, 81, 855-861.	2.4	21
12	SDHC epi-mutation testing in gastrointestinal stromal tumours and related tumours in clinical practice. Scientific Reports, 2019, 9, 10244.	3.3	20
13	Nephrogenic syndrome of inappropriate antidiuresis secondary to an activating mutation in the arginine vasopressin receptor AVPR2. Clinical Endocrinology, 2016, 85, 306-312.	2.4	19
14	Rapid disease progression in a patient with mismatch repair-deficient and cortisol secreting adrenocortical carcinoma treated with pembrolizumab. Seminars in Oncology, 2018, 45, 151-155.	2.2	19
15	Past, present and future strategies to study the genetics of body weight regulation. Briefings in Functional Genomics & Proteomics, 2002, 1, 290-304.	3.8	15
16	What is the appropriate management of nonfunctioning pancreatic neuroendocrine tumours disclosed on screening in adult patients with multiple endocrine neoplasia type 1?. Clinical Endocrinology, 2019, 91, 708-715.	2.4	14
17	A type III complement factor D deficiency: Structural insights for inhibition of the alternative pathway. Journal of Allergy and Clinical Immunology, 2018, 142, 311-314.e6.	2.9	13
18	Adult-onset hyperinsulinaemic hypoglycaemia in clinical practice: diagnosis, aetiology and management. Endocrine Connections, 2017, 6, 540-548.	1.9	12

#	Article	IF	Citations
19	Fumarate Metabolic Signature for the Detection of Reed Syndrome in Humans. Clinical Cancer Research, 2020, 26, 391-396.	7.0	11
20	A case of a metastatic SDHA mutated paraganglioma re-presenting twenty-three years after initial surgery. Endocrine-Related Cancer, 2017, 24, L69-L71.	3.1	10
21	Multiple endocrine neoplasia type 1 in children and adolescents: Clinical features and treatment outcomes. Surgery, 2021, , .	1.9	10
22	Metabolic dysfunction-related liver disease as a risk factor for cancer. BMJ Open Gastroenterology, 2022, 9, e000817.	2.7	10
23	Characterisation of proguanylin expressing cells in the intestine â€“ evidence for constitutive luminal secretion. Scientific Reports, 2019, 9, 15574.	3.3	8
24	Heterogeneity of glucagonomas due to differential processing of proglucagon-derived peptides. Endocrinology, Diabetes and Metabolism Case Reports, 2015, 2015, 150105.	0.5	7
25	Precision Medicine in Phaeochromocytoma and Paraganglioma. Journal of Personalized Medicine, 2021, 11, 1239.	2.5	7
26	An approach to a patient with primary hyperparathyroidism and a suspected ectopic parathyroid adenoma. Journal of Clinical Endocrinology and Metabolism, 2022, , .	3.6	4
27	Investigating the role of somatic sequencing platforms for phaeochromocytoma and paraganglioma in a large UK cohort. Clinical Endocrinology, 2022, 97, 448-459.	2.4	4
28	Breast cancer in multiple endocrine neoplasia type 1 (MEN1). Endocrinology, Diabetes and Metabolism Case Reports, 2021, 2021, .	0.5	2
29	A single centre retrospective analysis of cinacalcet therapy in primary hyperparathyroidism. Endocrine Connections, 2021, 10, 1435-1444.	1.9	2
30	Genetic Disorders of Insulin Action: Far More than Diabetes. Current Obesity Reports, 2013, 2, 293-300.	8.4	1
31	HEROIC: a 5-year observational cohort study aimed at identifying novel factors that drive diabetic kidney disease: rationale and study protocol. BMJ Open, 2020, 10, e033923.	1.9	1
32	Response to Letter to the Editor: â€œCT Characteristics of Pheochromocytoma: Relevance for the Evaluation of Adrenal Incidentalomaâ€• Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3842-e3843.	3.6	0
33	P0347COMPLEMENT FACTOR BB AND FACTOR C4D IN IGA NEPHROPATHY AND IGA VASCULITIS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
34	Investigating the clinical, pathological and molecular profile of oncocytic adrenocortical neoplasms: a case series and literature review. Endocrine Oncology, 2021, 1, 33-44.	0.4	0